CTLA4 and cancer: Dual ICIs such as tremelimumab plus durvalumab and nivolumab plus ipilimumab target proteins named PD-1 and CTLA-4 on T cells, respectively, helping to activate them to identify and attack cancer cells (Arru et al., 2021).